Despite solid literature findings supporting the implication of COX-2 in TMZ resistance of GBM [21,24], as far as we know, there is no evidence that the drug of choice for the most common primary malignant brain tumor in adults can influence COX-2 expression and/or activity in GBM cells. This evidence concerns the gene PTGS2 and glioblastoma.